What is Cellcolabs?
Cellcolabs, established in 2021 and headquartered in Stockholm, Sweden, is at the forefront of industrial-scale Mesenchymal Stromal Cell (MSC) production. The company is dedicated to revolutionizing treatments for severe diseases by providing high-quality MSCs at competitive prices for both research and clinical applications. Cellcolabs also focuses on facilitating future market approvals and is actively seeking research collaborations to accelerate progress in the MSC field, aiming to make stem cell therapies more accessible and affordable.
How much funding has Cellcolabs raised?
Cellcolabs has raised a total of $12M across 1 funding round:
Other Financing Round
$12M
Other Financing Round (2025): $12M with participation from TITAN Capital
Key Investors in Cellcolabs
TITAN Capital
TITAN Capital is an investment firm specializing in early-stage ventures, with a focus on impact investments across various industries including healthcare. They are known for their hands-on approach, providing strategic support to portfolio companies.
What's next for Cellcolabs?
The substantial enterprise-level funding indicates Cellcolabs is poised for significant scaling and market penetration. This capital injection is expected to accelerate the company's research and development initiatives, expand its production capabilities, and support its efforts to gain regulatory approvals for its MSC therapies. The strategic nature of the recent investment suggests a strong alignment with investor goals, potentially paving the way for key partnerships and market expansion in the rapidly growing regenerative medicine sector.
See full Cellcolabs company page
